BioSpace News Archive

Axsome Therapeutics, Inc. today announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder (ADHD) in adults.

Can-Fite invites individual and institutional investors as well as analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.

Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts.

Castle Biosciences, Inc. will present new data on its gene expression profile (GEP) risk-stratification test for patients with cutaneous squamous cell carcinoma (SCC), DecisionDx®-SCC, and its GEP risk-stratification test for patients with cutaneous melanoma (CM), DecisionDx®-Melanoma, at the American Head & Neck Society’s (AHNS) 11th International Conference.

BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100.

AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2023 financial results and third quarter 2023 outlook on Thursday, August 3, 2023, at 5:00 p.m. Eastern Time.

CytoSorbents Corporation announced that it has completed enrollment of the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor ( STAR-T ) randomized, controlled trial, evaluating the ability of DrugSorb ® -ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery on ticagrelor.

Xtant Medical Holdings, Inc. today announced the closing of its previously announced $15 million private placement with accredited investors.

280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the investigational drug YL-17231, a small molecule inhibitor of RAS signaling.

Acasti Pharma Inc. today announced that the Company will effect a 1-for-6 reverse split of its issued and outstanding common shares.